ADC Therapeutics Forecasts Q4 Loss, Full-Year Revenue of $80.6M; Analysts See 88.6% Upside
ADC Therapeutics is projected to report Q4 2025 revenue of $21.39 million and a loss of $0.28 per share, with full-year 2025 revenue estimated at $80.55 million and a loss of $1.40 per share. Four analysts set a $7.75 12-month target price implying 88.6% upside, while GF Value suggests downside.
1. Q4 2025 and Full-Year Projections
ADC Therapeutics is set to report Q4 2025 revenue of $21.39 million with a loss of $0.28 per share on March 10, 2026. Full-year 2025 revenue is projected at $80.55 million with earnings of -$1.40 per share.
2. Estimate Trend Revisions
Revenue estimates for 2025 have been raised from $76.65 million to $80.55 million, while 2026 revenue forecasts have slipped from $79.61 million to $78.47 million over the past 90 days. Earnings per share estimates improved slightly for both 2025 (from -$1.41 to -$1.40) and 2026 (from -$1.11 to -$1.10).
3. Previous Quarter Performance
In Q3 2025, ADC Therapeutics reported revenue of $16.43 million, missing the $17.08 million consensus by 3.8%. The company beat expectations on EPS at -$0.30 versus -$0.36, driving a one-day stock gain of 4.2%.
4. Analyst Price Targets and Valuation
Four analysts set a 12-month target price of $7.75 on average, ranging from $5.00 to $10.00, implying 88.6% upside. A GF Value estimate of $1.69 suggests downside of 58.9%, while broker recommendations average 1.5, signaling a buy bias.